JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Cyclosporine in psoriatic arthropathy.

Psoriatic arthropathy (PsA) is an inflammatory arthropathy associated with skin or nail psoriasis with heterogeneous clinical manifestations. A pragmatic therapeutic approach to PsA is to stratify the disease manifestations according to their response to synthetic and biological agents. It is now reasonably well established that peripheral arthritis is amenable to treatment with synthetic disease-modifying anti-rheumatic drugs, while psoriatic pelvispondylitis and inflammatory tendon lesions appear to require the use of biological agents. Cyclosporine is a calcineurin inhibitor belonging to the synthetic disease-modifying anti-rheumatic drugs group. It has been shown to be effective in treating both arthritis and psoriasis. In this paper, we will briefly summarise the current knowledge about the efficacy of cyclosporine, both as a monotherapy and as an adjunctive treatment for PsA.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app